Stay updated with breaking news from Bruce Strober. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For generalized pustular psoriasis, treatment with the subcutaneously administered IL-36 receptor antagonist resulted in a significant reduction in flares compared with placebo.
New clinical trial data shows benefits of spesolimab for GPP flares, providing compelling evidence for IL-36 signaling’s effect on the condition’s pathogenesis.
Today at the 25th World Congress of Dermatology WCD Boehringer Ingelheim presented new latebreaking data from the EFFISAYIL 2 trial showing that spesolimab significantly reduced the risk of GPP flares by 84 over 48 weeks compared to placebo.
An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, review the clinical and practical impact of TYK2 inhibition and its evolving role within the treatment landscape for psoriatic disease.